Condition: Autoimmune Cytopenia · Immune Thrombocytopenia (ITP) · Autoimmune Hemolytic Anemia · Sponsor: Keymed Biosciences Co.Ltd
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
This description comes directly from the study's public registry record.
Qian Jia · 86+028-88610620 · qianjia@keymedbio.com
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Heping Hospital Affiliated to Changzhi Medical College | Changzhi, Shanxi, China | Recruiting |
| Blood Disease Hospital, Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07175493